Infectious Disease Book

http://www.fpnotebook.com/

Hepatitis B VaccineAka: Hep B Vaccine

Advertisement

  1. Indications
    1. All Newborns (at birth, age 2 months, and age 6 months)
    2. All health care personnel
    3. Hemodialysis patients
    4. Patients requiring frequent blood transfusion
    5. Staff and residents at developmentally disabled home
    6. Male homosexuals and their sexual contacts
    7. Intravenous Drug Abuse
    8. Sexual contacts of chronic HBsAg carriers
    9. Consider for areas of high prevelance
      1. Asia
      2. Sub-Saharan Africa
  2. Contraindications
    1. Anaphylactic reaction to baker's yeast
  3. Efficacy
    1. Starting series after age 3 months may improve immunity
    2. Immunity appears to be lifelong after series
    3. References
      1. Kim (1997) Pediatrics 99:534
      2. Kane (2000) Lancet 355:561
  4. Available Preparations
    1. Recombivax HB
      1. Infants, Children and Adolescents: 5 ug/dose
      2. Adults: 10 ug/dose
      3. Immunosuppressed Adult: 20 ug/dose
    2. Energix-B (SKB)
      1. Infants and Children: 10 ug/dose
    3. Twinrix (Combined Hepatitis A and Hepatitis B Vaccine)
      1. Adults: 720 EU/20 ug (1.0 ml)
      2. Not approved for use in Children
      3. Requires 3 doses as in Hepatitis B Vaccine schedule
  5. Dosage: Protocols for Standard Schedule (Harmonized Schedule)
    1. Dose 1: Birth to age 2 months (first dose at age >1 month if birth weight <2000 grams)
    2. Dose 2: Age 1 to 4 months (>1 month after dose 1)
    3. Dose 3: Age 6 to 18 months (>2 months after dose 2)
  6. Alternative Protocols
    1. Rapid Vaccination (3 weeks) French Study
      1. French Protocol
        1. Regular: Days 0, 28, and 56
        2. Rapid: Days 0, 10, and 21
      2. Efficacy compared with regular French schedule
        1. Day 28: Higher seroprotection than reg schedule
        2. Day 56: Lower seroprotection than regular
        3. Day 365: Same seroprotection as regular schedule
      3. References
        1. Marchou (1995) J Infect Dis 172:258
    2. Moderately Rapid Vaccination schedule
      1. Rapid Schedule: months 0, 1, and 2
      2. Efficacy
        1. Month 3: Greater seroprotective effect
        2. Month 7: Equivalent seroprotection (100%)
          1. Higher Antibody titer for standard group
          2. Suggests possible longer term protection
      3. References
        1. Marsano (1996) Am J Gastroenterol 91:111
  7. Management: Infant with HBsAg Positive Mother
    1. Administer HBig and Hepatitis B Vaccine
      1. Hepatitis B Immunoglobulin (HBIG)
        1. Dose: 0.5 ml within 12 hours of birth
      2. Hepatitis B Vaccine starting with dose in hospital
        1. Dose 1: Within 12 hours of birth
        2. Dose 2: Age 1 months
        3. Dose 3: Age 6 months
        4. Additional Dose: Age 2 months if birth weight <2000 grams
    2. Labs at 9 and 15 months of age
      1. Hepatitis B Surface Antigen (HBsAg)
      2. Hepatitis B Surface Antibody (HBsAb)
  8. Precautions
    1. Safe in HIV
      1. See Immunization in HIV
    2. Safe in Pregnancy
      1. See Immunization in Pregnancy
  9. Adverse Effects
    1. One reaction per 600,000 doses
    2. References
      1. (1996) MMWR Morb Mortal Wkly Rep 45(No. RR-12):1
  10. References
    1. (2001) Med Lett Drugs Ther 43(1110):67

Hepatitis B Vaccine (C0062527)

Definition (MSH)Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced.
Definition (PDQ)A non-infectious mixture containing recombinant hepatitis B surface antigen (HBsAg) in a liquid vehicle. Immunization with the hepatitis B vaccine induces the formation of specific anti-hepatitis B antibodies and an active immunity against hepatitis B infection. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=532310&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=532310&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29091" NCI Thesaurus)
Definition (NCI)A non-infectious mixture containing recombinant hepatitis B surface antigen (HBsAg) in a liquid vehicle. Immunization with the hepatitis B vaccine induces the formation of specific anti-hepatitis B antibodies and an active immunity against hepatitis B infection. (NCI04)
Definition (HL7V3.0)hepatitis B vaccine, NOS
ConceptsOrganic Chemical (T109) , Pharmacologic Substance (T121) , Immunologic Factor (T129)
MSHD017325
EnglishHBIG - Hepatitis B vaccine, Hep B - Hepatitis B vaccine, HEPATITIS B, Hepatitis B Vaccine, HEPATITIS B VACCINE PREPARATION, Hepatitis B Vaccines, Hepatitis B virus vaccine, Hepatitis B virus vaccine inactivated
Spanishvacuna contra el virus de la hepatitis B, vacuna inactivada anti-hepatitis B
Parent ConceptsVaccines administered (code = CVX)(parenteral, unless oral is noted) (C1547693), VaccineType (C1554000), Viral Hepatitis Vaccines (C0042723), recombinant viral vaccine (C0281606), Vaccines (C0042210), Unclassified Ingredients (C1372954), Viral Vaccines (C0042742)
SourcesHL7V2.5, HL7V3.0, MSH, MTH, NCI, NDFRT, PDQ, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF
Derived from the NIH UMLS (Unified Medical Language System)



Navigation Tree